• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
Logo of annrheumdAnnals of the Rheumatic DiseasesView this articleSubmit a manuscriptReceive email alertsContact usBMJ
Ann Rheum Dis. Mar 2004; 63(3): 245–251.
PMCID: PMC1754917

Increased DNA fragmentation and ultrastructural changes in fibromyalgic muscle fibres

Abstract

Objective: To determine whether there is evidence of increased DNA fragmentation and ultrastructural changes in muscle tissue of patients with fibromyalgia (FM) compared with healthy controls.

Methods: Muscle tissues from 10 community residents with FM and 10 age and sex matched healthy controls were examined "blindly" for the presence of DNA fragmentation by two different methods: terminal deoxynucleotidyl transferase (TdT) staining (TUNEL) and the FragEL-Klenow DNA fragmentation detection kit. Ultrastructural analysis of tissue was performed by electron microscopy.

Results: DNA fragmentation was detected by both methods in 55.4 (SEM 2.5)% of the nuclei in muscle tissue of patients with FM compared with 16.1 (4.1)% (p<0.001) of the nuclei in healthy controls. Contrary to expectation, no typical features of apoptosis could be detected by electron microscopy. The myofibres and actin filaments were disorganised and lipofuscin bodies were seen; glycogen and lipid accumulation were also found. The number of mitochondria was significantly lower in patients with FM than in controls and seemed to be morphologically altered.

Conclusion: The ultrastructural changes described suggest that patients with FM are characterised by abnormalities in muscle tissue that include increased DNA fragmentation and changes in the number and size of mitochondria. These cellular changes are not signs of apoptosis. Persistent focal contractions in muscle may contribute to ultrastructural tissue abnormalities as well as to the induction and/or chronicity of nociceptive transmission from muscle to the central nervous system.

Full Text

The Full Text of this article is available as a PDF (683K).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Wolfe F. Fibromyalgia: the clinical syndrome. Rheum Dis Clin North Am. 1989 Feb;15(1):1–18. [PubMed]
  • Russell IJ, Orr MD, Littman B, Vipraio GA, Alboukrek D, Michalek JE, Lopez Y, MacKillip F. Elevated cerebrospinal fluid levels of substance P in patients with the fibromyalgia syndrome. Arthritis Rheum. 1994 Nov;37(11):1593–1601. [PubMed]
  • Crofford LJ, Pillemer SR, Kalogeras KT, Cash JM, Michelson D, Kling MA, Sternberg EM, Gold PW, Chrousos GP, Wilder RL. Hypothalamic-pituitary-adrenal axis perturbations in patients with fibromyalgia. Arthritis Rheum. 1994 Nov;37(11):1583–1592. [PubMed]
  • Mountz JM, Bradley LA, Modell JG, Alexander RW, Triana-Alexander M, Aaron LA, Stewart KE, Alarcón GS, Mountz JD. Fibromyalgia in women. Abnormalities of regional cerebral blood flow in the thalamus and the caudate nucleus are associated with low pain threshold levels. Arthritis Rheum. 1995 Jul;38(7):926–938. [PubMed]
  • Weigent DA, Bradley LA, Blalock JE, Alarcón GS. Current concepts in the pathophysiology of abnormal pain perception in fibromyalgia. Am J Med Sci. 1998 Jun;315(6):405–412. [PubMed]
  • Gracely Richard H, Petzke Frank, Wolf Julie M, Clauw Daniel J. Functional magnetic resonance imaging evidence of augmented pain processing in fibromyalgia. Arthritis Rheum. 2002 May;46(5):1333–1343. [PubMed]
  • Staud R, Vierck CJ, Cannon RL, Mauderli AP, Price DD. Abnormal sensitization and temporal summation of second pain (wind-up) in patients with fibromyalgia syndrome. Pain. 2001 Mar;91(1-2):165–175. [PubMed]
  • Jacobsen S, Bartels EM, Danneskiold-Samsøe B. Single cell morphology of muscle in patients with chronic muscle pain. Scand J Rheumatol. 1991;20(5):336–343. [PubMed]
  • Yunus MB, Kalyan-Raman UP, Masi AT, Aldag JC. Electron microscopic studies of muscle biopsy in primary fibromyalgia syndrome: a controlled and blinded study. J Rheumatol. 1989 Jan;16(1):97–101. [PubMed]
  • Yunus MB, Kalyan-Raman UP. Muscle biopsy findings in primary fibromyalgia and other forms of nonarticular rheumatism. Rheum Dis Clin North Am. 1989 Feb;15(1):115–134. [PubMed]
  • Simms RW, Roy SH, Hrovat M, Anderson JJ, Skrinar G, LePoole SR, Zerbini CA, de Luca C, Jolesz F. Lack of association between fibromyalgia syndrome and abnormalities in muscle energy metabolism. Arthritis Rheum. 1994 Jun;37(6):794–800. [PubMed]
  • Anders C, Sprott H, Scholle HC. Surface EMG of the lumbar part of the erector trunci muscle in patients with fibromyalgia. Clin Exp Rheumatol. 2001 Jul-Aug;19(4):453–455. [PubMed]
  • Park JH, Phothimat P, Oates CT, Hernanz-Schulman M, Olsen NJ. Use of P-31 magnetic resonance spectroscopy to detect metabolic abnormalities in muscles of patients with fibromyalgia. Arthritis Rheum. 1998 Mar;41(3):406–413. [PubMed]
  • Sprott H, Rzanny R, Reichenbach JR, Kaiser WA, Hein G, Stein G. 31P magnetic resonance spectroscopy in fibromyalgic muscle. Rheumatology (Oxford) 2000 Oct;39(10):1121–1125. [PubMed]
  • Jubrias SA, Bennett RM, Klug GA. Increased incidence of a resonance in the phosphodiester region of 31P nuclear magnetic resonance spectra in the skeletal muscle of fibromyalgia patients. Arthritis Rheum. 1994 Jun;37(6):801–807. [PubMed]
  • Choi YB, Lipton SA. Redox modulation of the NMDA receptor. Cell Mol Life Sci. 2000 Oct;57(11):1535–1541. [PubMed]
  • Larson AA, Giovengo SL, Russell IJ, Michalek JE. Changes in the concentrations of amino acids in the cerebrospinal fluid that correlate with pain in patients with fibromyalgia: implications for nitric oxide pathways. Pain. 2000 Aug;87(2):201–211. [PubMed]
  • Yunus MB, Kalyan-Raman UP, Kalyan-Raman K, Masi AT. Pathologic changes in muscle in primary fibromyalgia syndrome. Am J Med. 1986 Sep 29;81(3A):38–42. [PubMed]
  • Fawthrop DJ, Boobis AR, Davies DS. Mechanisms of cell death. Arch Toxicol. 1991;65(6):437–444. [PubMed]
  • Wyllie AH, Kerr JF, Currie AR. Cell death: the significance of apoptosis. Int Rev Cytol. 1980;68:251–306. [PubMed]
  • Duke RC, Chervenak R, Cohen JJ. Endogenous endonuclease-induced DNA fragmentation: an early event in cell-mediated cytolysis. Proc Natl Acad Sci U S A. 1983 Oct;80(20):6361–6365. [PMC free article] [PubMed]
  • Wyllie AH. Glucocorticoid-induced thymocyte apoptosis is associated with endogenous endonuclease activation. Nature. 1980 Apr 10;284(5756):555–556. [PubMed]
  • Gavrieli Y, Sherman Y, Ben-Sasson SA. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol. 1992 Nov;119(3):493–501. [PMC free article] [PubMed]
  • Aaron LA, Bradley LA, Alarcón GS, Alexander RW, Triana-Alexander M, Martin MY, Alberts KR. Psychiatric diagnoses in patients with fibromyalgia are related to health care-seeking behavior rather than to illness. Arthritis Rheum. 1996 Mar;39(3):436–445. [PubMed]
  • Wolfe F, Smythe HA, Yunus MB, Bennett RM, Bombardier C, Goldenberg DL, Tugwell P, Campbell SM, Abeles M, Clark P, et al. The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis Rheum. 1990 Feb;33(2):160–172. [PubMed]
  • Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AD. The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol. 1989 Oct;46(10):1121–1123. [PubMed]
  • Melzack R. The McGill Pain Questionnaire: major properties and scoring methods. Pain. 1975 Sep;1(3):277–299. [PubMed]
  • Gavrieli Y, Sherman Y, Ben-Sasson SA. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol. 1992 Nov;119(3):493–501. [PMC free article] [PubMed]
  • Spurr AR. A low-viscosity epoxy resin embedding medium for electron microscopy. J Ultrastruct Res. 1969 Jan;26(1):31–43. [PubMed]
  • Graven-Nielsen T, Aspegren Kendall S, Henriksson KG, Bengtsson M, Sörensen J, Johnson A, Gerdle B, Arendt-Nielsen L. Ketamine reduces muscle pain, temporal summation, and referred pain in fibromyalgia patients. Pain. 2000 Apr;85(3):483–491. [PubMed]
  • Wolfe F, Ross K, Anderson J, Russell IJ, Hebert L. The prevalence and characteristics of fibromyalgia in the general population. Arthritis Rheum. 1995 Jan;38(1):19–28. [PubMed]
  • White KP, Speechley M, Harth M, Ostbye T. The London Fibromyalgia Epidemiology Study: the prevalence of fibromyalgia syndrome in London, Ontario. J Rheumatol. 1999 Jul;26(7):1570–1576. [PubMed]
  • Wei YH, Kao SH, Lee HC. Simultaneous increase of mitochondrial DNA deletions and lipid peroxidation in human aging. Ann N Y Acad Sci. 1996 Jun 15;786:24–43. [PubMed]
  • Kersh BC, Bradley LA, Alarcón GS, Alberts KR, Sotolongo A, Martin MY, Aaron LA, Dewaal DF, Domino ML, Chaplin WF, et al. Psychosocial and health status variables independently predict health care seeking in fibromyalgia. Arthritis Rheum. 2001 Aug;45(4):362–371. [PubMed]
  • Sandri M, Carraro U, Podhorska-Okolov M, Rizzi C, Arslan P, Monti D, Franceschi C. Apoptosis, DNA damage and ubiquitin expression in normal and mdx muscle fibers after exercise. FEBS Lett. 1995 Oct 16;373(3):291–295. [PubMed]
  • Kirtava Z, Mdinaradze-Kirtava DK, Jacobsson L, Manthorpe R. Fibromyalgia and disability. Scand J Rheumatol. 1995;24(6):395–396. [PubMed]
  • Sprott Haiko. What can rehabilitation interventions achieve in patients with primary fibromyalgia? Curr Opin Rheumatol. 2003 Mar;15(2):145–150. [PubMed]
  • Häkkinen Keijo, Pakarinen Arto, Hannonen Pekka, Häkkinen Arja, Airaksinen Olavi, Valkeinen Heli, Alen Markku. Effects of strength training on muscle strength, cross-sectional area, maximal electromyographic activity, and serum hormones in premenopausal women with fibromyalgia. J Rheumatol. 2002 Jun;29(6):1287–1295. [PubMed]
  • Richards Selwyn C M, Scott David L. Prescribed exercise in people with fibromyalgia: parallel group randomised controlled trial. BMJ. 2002 Jul 27;325(7357):185–185. [PMC free article] [PubMed]

Figures and Tables

Figure 1
DNA fragmentation staining (dark dots, black arrow) with the Klenow method in muscle tissue of subjects with FM (B) compared with healthy controls (A). Blue staining (white arrow) shows nuclei without DNA fragmentation (original magnification x200).
Figure 2
Electron micrograph of muscle tissue from a healthy control (A) and from a subject with FM (B) showing zig-zagging of the Z bands. L shows a lipid droplet. M and the white arrow shows a mitochondrion (A). There are no mitochondria in the selected anatomical ...
Figure 3
Electron micrograph of muscle tissue from a healthy control (A) for comparison and from subjects with FM (B-D) with different duration of symptoms: (B) 1 year; (C) 8 years; (D) 20 years. Black arrows indicate mitochondria (A, D). The open arrow indicates ...

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Group

Formats:

Related citations in PubMed

See reviews...See all...

Cited by other articles in PMC

See all...

Links

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...